Bristol Myers Squibb reported Q4 2024 revenues of $12.3 billion, increasing 8% YoY (9% excluding foreign exchange), driven by Growth Portfolio expansion and higher Eliquis demand. Growth Portfolio revenues rose 21% to $6.4 billion, while Legacy Portfolio declined 4% to $6.0 billion. GAAP EPS was $0.04 and Non-GAAP EPS was $1.67.The company achieved significant milestones including U.S. approval of Opdivo Qvantig and launch of Cobenfy for schizophrenia treatment. Full-year 2024 revenues reached $48.3 billion, up 7% YoY, with Growth Portfolio revenues increasing 17% to $22.6 billion. However, GAAP showed a loss per share of $(4.41) while Non-GAAP EPS was $1.15.Looking ahead, BMS expanded its strategic productivity initiative targeting $2 billion in additional cost savings by 2027. The company provided 2025 guidance with projected revenues of approximately $45.5 billion and Non-GAAP EPS range of $6.55-$6.85, reflecting continued growth in key products despite expected generic impacts on Legacy Portfolio.

Bristol Myers Squibb reported Q4 2024 revenues of $12.3 billion, increasing 8% YoY (9% excluding foreign exchange), driven by Growth Portfolio expansion and higher Eliquis demand. Growth Portfolio revenues rose 21% to $6.4 billion, while Legacy Portfolio declined 4% to $6.0 billion. GAAP EPS was $0.04 and Non-GAAP EPS was $1.67.The company achieved significant milestones including U.S. approval of Opdivo Qvantig and launch of Cobenfy for schizophrenia treatment. Full-year 2024 revenues reached $48.3 billion, up 7% YoY, with Growth Portfolio revenues increasing 17% to $22.6 billion. However, GAAP showed a loss per share of $(4.41) while Non-GAAP EPS was $1.15.Looking ahead, BMS expanded its strategic productivity initiative targeting $2 billion in additional cost savings by 2027. The company provided 2025 guidance with projected revenues of approximately $45.5 billion and Non-GAAP EPS range of $6.55-$6.85, reflecting continued growth in key products despite expected generic impacts on Legacy Portfolio.